Sign up USA
Proactive Investors - Run By Investors For Investors

Marinus Pharmaceuticals Inc shares soar on early study results

Enrollment is continuing in the study with top-line data expected in mid-2017
Marinus Pharmaceuticals Inc shares soar on early study results
The data comes from initial CDKL5 patients enrolled in an ongoing Phase 2 open-label study, the company said

Shares in Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shot up almost 40% as it posted positive clinical study findings.

The data comes from initial CDKL5 patients enrolled in an ongoing Phase 2 open-label study evaluating its ganaxolone candidate as a treatment for orphan, genetic disorders.

CDKL5 is a severe, rare genetic disorder that results in early-onset, difficult-to-control seizures.

Enrollment is continuing in the study with top-line data expected in mid-2017.

“We are encouraged by the results in these difficult-to-treat pediatric patients,” said Dr. Jaakko Lappalainen, vice president of clinical development at the company.

“Concurrent with completing this study, we will be evaluating the potential for breakthrough therapy and applying for orphan drug designation with the United States Food and Drug Administration.

"CDKL5 pediatric epilepsy may prove to be an attractive and efficient path for ganaxolone and we look forward to evaluating results from the final patients enrolled in this cohort of the study.”

Shares in New York are at US$1.61 - an increase of 38.79% at the time of writing.



Register here to be notified of future MRNS Company articles
View full MRNS profile View Profile

Marinus Timeline

Related Articles

Regeneus: Access latest PPT from Proactive's CEO Sessions
Sun
John Martin discussed regenerative medicine with investors.
Drugs
May 03 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
antibiotic.jpg
April 18 2017
Iclaprim is one of the next-generation of antibiotics and it will be used, initially at least, to treat acute bacterial skin and skin structure infections
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use